Prothena | PRTA - Operating Expenses


Prothena reported $25.29M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 11.69B 6.9B Jun/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Exelixis USD 380.28M 20.8M Jun/2026
Immunic USD 23.33M 2.67M Dec/2025
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Prothena USD 25.29M 1.94M Mar/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026